Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other ...

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol ...

Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...